Cantor Fitzgerald maintains overweight rating on Bicara stock
Investing.com
Published Jun 03, 2025 07:51AM ET
On Tuesday, Cantor Fitzgerald analysts reiterated an Overweight rating on Bicara Therapeutics Inc (NASDAQ: BCAX). The decision follows a meeting with the company's management after the release of Phase 1b data at the American Society of Clinical Oncology (ASCO) conference. According to InvestingPro data, BCAX maintains a strong liquidity position with a current ratio of 24.6 and holds more cash than debt on its balance sheet.
The analysts expressed confidence in Bicara's drug ficerafusp, highlighting its potential advantages over MRUS' petosemtamab. They noted that while MRUS may have gained attention from investors due to ASCO data updates, they believe ficerafusp presents significant points of differentiation. The broader analyst consensus remains bullish, with an average rating of 1.57 (where 1 is Strong Buy).
Despite a positive outlook from key opinion leaders (KOLs), the analysts pointed out a disconnect between these experts and the broader investment community. Bicara's market capitalization stands at approximately $540 million, just above its cash balance, compared to MRUS' $4 billion market cap. InvestingPro analysis suggests BCAX is currently undervalued, with analyst targets ranging from $8 to $48 per share.
The analysts emphasized their belief in the potential of ficerafusp and suggested that the gap between market perception and expert opinion should narrow. They reiterated their positive stance on Bicara's prospects in the current market environment. Discover 10 additional exclusive insights about BCAX on InvestingPro .
In other recent news, Bicara Therapeutics has shared updated interim data from its Phase 1/1b clinical trial, revealing promising results for its treatment of recurrent/metastatic head and neck squamous cell carcinoma (HNSCC). The data, now available on the American Society of Clinical Oncology (ASCO) Annual Meeting website, highlights a 64% objective response rate in the HPV-negative population, with a 12-month overall survival rate of 61%. Despite these positive figures, the publication of the interim results led to a 30% drop in the company's stock in after-hours trading. Analysts from Stifel and Cantor Fitzgerald have reiterated their positive outlook on Bicara, with Stifel maintaining a Buy rating and a $48 price target, and Cantor Fitzgerald reiterating an Overweight rating. Both firms expressed confidence in the potential of Bicara’s lead therapeutic candidate, ficerafusp alfa. The analysts noted that more than 80% of responders treated with ficerafusp achieved significant tumor shrinkage, suggesting improved clinical outcomes. Bicara plans to present a comprehensive dataset, including overall survival and duration of response data, at an upcoming ASCO Annual Meeting. This presentation will be led by Dr. Christine Chung from the Moffitt Cancer Center, providing further insights into the drug's efficacy and safety profile.
Get The News You Want
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.
Written By: Investing.com
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.